Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin for Essential Tremor using Kinematic Assessment
NCT02551848Phase 2
Key facts
- Status
- Unknown
- Start
- Aug 2014
- Primary completion
- Sep 2020
- Countries
- 1
- Sponsor
- Western University
- Conditions
- essential tremor (ET)
01
Overview
Phase 2, open-label trial of botulinum toxin type A in essential tremor (ET), sponsored by Western University. Primary endpoint: Kinematic tremor severity at 72 weeks. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Patients with definite essential tremor who are botulinum toxin naive and on stable ET medication for at least 3 months.
04
Endpoints
Primary
Kinematic tremor severity
Secondary
Clinical tremor severity
Accelerometric kinematic tremor severity
Beyond the preview
Go deeper on NCT02551848.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02551848.